Home / 2021 / April / 13

Daily Archives: April 13, 2021

INTELEX RELEASES ESG SOLUTION TO POWER THE SHIFT FROM SUSTAINABILITY REPORTING TO BUSINESS VALUE CREATION

New solution offers streamlined ESG-related program management and disclosure reporting for increased efficiency and transparency on corporate environmental and societal impact evaluation

TORONTO, CANADA, April 13, 2021 (GLOBE NEWSWIRE) — Intelex Technologies, ULC, a leading global provider of SaaS-based Environmental, Health, Safety and Quality (EHSQ) management software, today announced the general availability of a new suite of Environmental, Social, and Corporate Governance (ESG) management solutions that will help organizations launch, scale, or optimize their ESG programs, regardless of where they are at in their program maturity.

Companies are under unprecedented pressure to meet increasing market demand for transparency of non-financial reporting of ESG performance. ESG is no longer optional and is quickly becoming a differentiator and an indicator of long-term business value. Intelex’s ESG Management solution tackles obstacles faced by organizations to collect, share, and improve upon key ESG criteria across environmental and sustainability, worker health and safety, quality, supplier management, and beyond. The solution packages a broad range of functionality associated with sustainability reporting requirements such as the Global Reporting Initiative (GRI) or Carbon Disclosure Project (CDP), and includes broader capabilities to address the needs for companies to enhance ESG management, conduct more robust assessments, and track how projects improve performance against KPIs over time.

“With the momentum surrounding sustainable finance showing no signs of slowing down, ESG management has shifted from reporting to business value creation”, said Brian Ice, chief product and engineering officer at Intelex. “The Intelex ESG solution enables our customers to deliver positive outcomes to shareholders and stakeholders alike and strengthens our ability to deliver high-value and high-impact technology tools for this new era of sustainable business.”

Key highlights of the solution include:

  • Centralized view of critical ESG information: The solution breaks down data siloes that bog down notoriously broad ESG data collection, providing users with a centralized view of ESG information.
  • Historical ESG performance data and trends: Users can easily track performance of ESG KPIs over time to demonstrate ongoing improvements, including supplier KPI tracking, as well as stakeholder management.
  • Integration with disparate ESG data sources:  While ESG data and metrics can be entered manually, the solution also provides the ability for automated, near real-time integration with data collection systems including HRIS, Payroll, Utility Management, Asset Management, ERP systems and more.
  • Sustainability and ESG reporting: The solution enables reporting against the DRI, CDP, DJSI, SASB and the UN Guiding Principles. It further includes more than 20 US EPA Mandatory Reporting Rule (MRR) subparts, as well as management of multi-emission factor databases such as the California Climate Action Registry (CCAR), The Climate Registry, eGRID, the GHG Protocol, and the databases of the IEA and the IPCC.
  • Automated audit trail capabilities: Automated audit trails, configuration tools, and intuitive formula generation ensures users can access next to real-time KPIs in a timely manner.
  • Initiative and project management: Sub-projects and initiatives that collectively contribute to the larger ESG goals can be managed via initiative and project management functionality that allows users set targets, create tasks and sub-tasks, assign key stakeholders, track completion status, escalate overdue items, and analyze real-time performance.
  • Robust calculation engine: Users can run calculations on extremely large data sets, such as emissions and carbon footprint data, waste generation, and climate change resiliency, at speeds of a million calculations per hour.
  • Access to ESG management experts:  Customers gain access to industry-leading in-house environment and sustainability, health, safety, and ESG experts that cater program definition and software configuration best practices to meet unique needs of the company and its ESG program maturity.

Intelex’s ESG solution goes beyond data collection and reporting, facilitating a broad scope of performance improvement via best-practice workflows, a robust task management engine, and powerful dashboards and analytical tools that promote cross-organizational transparency, accountability, and communication. It is available in four flexible packages to address the varying stages of ESG program maturity in the market.

Intelex and independent research firm, Verdantix, will be hosting a live webinar, “The Urgency For ESG: Making the Leap From Reporting To Business Value”  on April 22, 2021 to share insights and best practices on the current ESG priorities companies should address, the frameworks to consider, and how to build an ESG program enabled with the right data to demonstrate ESG performance progress. The webinar is complimentary. Registration for the webinar is available at https://www.intelex.com/resources/upcoming-webinar/upcoming-webinar-urgency-esg-making-leap-reporting-business-value.

To learn more about the Intelex ESG solution suite, visit https://www.intelex.com/products/applications/esg-management.

ADDITIONAL RESOURCES

Blog – How is Renewable Energy Accelerating the Rise of Sustainable Business:  https://blog.intelex.com/2021/04/13/how-is-renewable-energy-accelerating-the-rise-of-sustainable-business/

About Intelex Technologies, ULC 

Intelex Technologies, ULC is a global leader in environmental, health, safety and quality (EHSQ) management software. Since 1992, Intelex employees across the globe have been committed to innovating and enabling organizations to send their employees home safely every day, leaving behind a more sustainable world to the generations that follow, and manage quality so that only the safest and highest quality products make it to market. Intelex’s scalable, web-based platform and applications have helped clients across all industries improve business performance, mitigate organization-wide risk, and ensure sustained compliance with internationally accepted standards (e.g. ISO 9001, ISO 14001, ISO 45001, and OHSAS 18001) and regulatory requirements. Almost 1,400 customers in 195 countries trust Intelex to power their EHSQ initiatives. Headquartered in Toronto with regional offices and employees around the world, Intelex became an Industrial Scientific company in 2019. In 2020, Intelex acquired ehsAI, provider of a SaaS-based next-wave compliance automation solution that leverages artificial intelligence and machine learning algorithms. For more information about Intelex, visit www.intelex.com.

Attachment

Roula Vrsic
Intelex Technologies, ULC
647-539-9551
roula.vrsic@intelex.com

Global Employee Relocations Served by WHR’s International Offices

MILWAUKEE, Wis., April 13, 2021 (GLOBE NEWSWIRE) — During 2020, WHR Group, Inc. (WHR) opened international offices in Singapore, and Basel, Switzerland, to support its global employee relocation services. These offices provide a range of services including pre-assignment, transition, on assignment and repatriation services to multi-language expatriate transferees. Along with its U.S. headquarters in Milwaukee, Wis., WHR helps some of the largest organizations in the world and has relocated hundreds of thousands of employees to over 120 countries worldwide.

Solely and independently owned since its inception 26 years ago, WHR specializes in providing each expatriate with a dedicated relocation team, white glove service and 24/7 availability for the entire relocation process – long or short-term assignments.

The Switzerland office supports clients and their transferees in Europe, the Middle East and Africa, while the Singapore office supports the Asia Pacific region. “While Covid-19 dramatically slowed the ability of individuals to cross borders, we persisted in opening these offices to fulfil our client obligations and be prepared to meet future demand,” says WHR President, Paul De Boer. “We anticipate a very healthy rebound once the pandemic ends, and we have our foundation in place to service any global expansion our clients demand.”

About WHR Group, Inc.
WHR Group Inc. (WHR) is a privately owned, client-driven global relocation management company distinguished by its best-in-class service delivery and cutting-edge, proprietary technology. WHR has offices in Milwaukee, Wis., Switzerland, and Singapore. With its 100% client retention rate for the past decade, WHR continues to position itself as the trusted provider in global employee relocation. To learn more about WHR, visit http://www.whrg.com, or follow @WHRGroup on LinkedIn, Twitter and Facebook.

Media Contact
Mindy Stroiman, Corporate Writer
Email: Mindy.Stroiman@whrg.com
Phone: 262-523-7510

Nikkiso Cryo Inc. New Facility Increases Cryogenic Pump Production

LAS VEGAS, April 13, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryo Inc. (NCI), Las Vegas NV, a member of Nikkiso Clean Energy and Industrial Gases Group (Group), a part of Nikkiso Co., Ltd (Japan) announces their new facility which increases their cryogenic pump production efficiency and capability.

NCI’s new, larger facility was necessary due to continued growth and demand for the cryogenic pump products and services they provide to the global LNG market (primarily for LNG export and import terminals).

The 15,000 square foot office facility is adjacent to their primary production test site, which includes several significant enhancements to operational efficiency, safety, and increased production capabilities. Among them is a new ground-level flare system which offers greater efficiency and manufacturing capacity. A Class 1 Division 1 electric overhead crane was installed on the test pad. This reduces costs, increases productivity by allowing multiple operations to occur simultaneously, improves safety by allowing multi-pump lifting and installation for testing and is certified for hazardous-rated areas.

“This is an exciting next step for our company and a significant benefit for our customers. NCI will now be able to increase production and reduce turn-around time,” according to Daryl Lamy, President of Nikkiso Cryo Inc.

These enhancements also provide benefits for customer remote-site witness testing at the facility. This feature offers significant value and time savings for global customers, particularly beneficial due to COVID-19 travel concerns.

ABOUT NIKKISO CRYO
Nikkiso Cryo, Inc. is a leading supplier of cryogenic submerged electric motor pumps used in the liquefied gas industry. NCI’s innovative designs have resulted in the first application of high-pressure pumps for use on regasification LNG carriers, the first and only cryogenic pumps installed on an LNG GBS, compact high flow pumps for the world’s largest FPSO under construction, as well as compact, higher speed pumps used for a variety of LNG, LPG and other applications.

For more information please visit www.nikkisoceig.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Tim Born becomes Vice President, Oceania and South East Asia for Nikkiso Clean Energy & Industrial Gases Group

TEMECULA, Calif., April 13, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a subsidiary of Nikkiso Co., Ltd (Japan), is pleased to announce that Tim Born has been appointed as the Vice President of Oceania and South East Asia Region.

This important addition to our management team is in line with the objectives of the Industrial Division of Nikkiso to better serve and support our customers in strategic territories.

Tim started his career in 1983, as a Production Engineer with BOC Gases, and later held several positions as Plant Manager, Commissioning and Senior Process Engineer, and Customer Engineering Services Manager with the same group, with roles in Australia and the UK.

In 1997, Tim joined Porgera Joint Venture Gold Mine (PNG) as a Senior Process Engineer operating large scale ASU’s, then moved to Air & Gas Industries in 1999, as an Installation and Engineering Manager.

In 2000, Tim joined Cryoquip Pty Ltd, as the General Manager, and in 2012 appointed as the Managing Director of the legal entity in Australia.

In 2020, Tim was promoted to the role of Vice President Cryoquip – South East Asia.

Tim has a Chemical Engineering Degree from the University of Melbourne, and a Masters in Business Administration from the University of Queensland.

With his vast experience in managing and growing the Cryoquip business line in Australia, South East Asia, and India, Tim will lead the Nikkiso Clean Energy & Industrial Gases teams in this important region, and embark on a mission to deliver market share growth in a sustainable and profitable way.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly-controlled group of approximately 20 operating entities.

For more information please visit www.cryoind.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Congenica and Camtech Diagnostics agree strategic partnership to support genomic analysis platform expansion in Asia

Congenica and Camtech Diagnostics agree strategic partnership to support genomic analysis platform expansion in Asia

Cambridge, United Kingdom and Singapore – 13 April 2021Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a strategic partnership with Camtech Diagnostics (“Camtech”), a technology company providing total solutions to the biodefence, food and clinical diagnostics sectors. The partnership covers the distribution of Congenica’s platform in Asia-Pacific.

Under the partnership agreement Camtech will be responsible for the marketing, distribution and sales of Congenica’s clinical decision support platform in Singapore, Malaysia, Japan and South Korea. Congenica’s leading technology platform is proven to enable rapid analysis of genomic data, allowing medical labs to deliver personalised medicine at scale. Congenica has an existing presence in China and this latest agreement will support continued expansion in the rare disease market in the Asia-Pacific region.

Camtech has significant experience in the healthcare diagnostics industry, having launched novel laboratory-based and point-of-care diagnostic tests to the market. It also has expertise in Next Generation Sequencing, laboratory based and digital health solutions, which will be complementary to Congenica’s solution.

Muthu Meyyappan, PhD, Chief Commercial Officer, Congenica, said: Camtech benefits from a strong reputation in Southeast Asia with an established network through which our platform can be rapidly distributed and integrated into rare disease diagnostic procedures. Global expansion remains a priority for Congenica and entry into these key territories signifies further strategic progress whilst opening up significant new markets for Congenica’s leading genomic analysis platform.”

Kuok Meng-Han, PhD, Managing Director, Camtech, said: “The advanced healthcare systems of Asia Pacific have been undergoing rapid development and growth. They have a clear need for fast, reliable tools to support the diagnosis of rare diseases. We believe that Congenica’s market leading genomic analysis platform has the potential to make a significant impact in the region. We are excited to partner with Congenica to rollout this platform and move closer to genomic medicine being more widely incorporated into standard clinical practice.”

About Congenica

Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers to provide life-changing answers that improve wellbeing and disease management.

Congenica’s world-leading software enables rapid genomic data analysis at scale, performing 20x faster than industry averages and providing a 30% higher analytical yield, reducing genomic interpretation costs by up to 95%.

Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

For more information visit www.congenica.com.

About Camtech Diagnostics

Camtech Diagnostics aims to enable ideal human health and wellness through technology and innovation in testing.

Founded in 2013, its vision is to provide novel diagnostic tests and digital solutions to obtain the most accurate real-time data and actionable insights for personalised health

It develops and commercialises a range of testing solutions for biodefence, food and clinical diagnostics applications, that aim to disrupt current lab-based testing approaches and has built significant R&D and Manufacturing capabilities to support these developments.

For more information visit www.camtechdiagnostics.com

Contact details for editorial enquiries:

Chris Gardner, Angela Gray, David Daley

Email: Congenica@consilium-comms.com

Tel: +44 (0)20 3709 5700

Noah Konig, Head of Marketing at Congenica

Email: noah.konig@congenica.com

Alvin Liew, Head of Corporate Affairs at Camtech

Email: alvin@camtech.com.sg

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

 PRESS RELEASE

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the
 American Association for Cancer Research 2021 Annual Meeting

Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma

First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor  

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 April 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator’s choice in first-line metastatic uveal melanoma (mUM) in the clinical trial plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Tebentafusp demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in mUM.  The OS Hazard Ratio (HR) in the intent-to-treat population favored tebentafusp, HR=0.51 (95% CI: 0.37, 0.71); p< 0.0001, over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine). Treatment-related adverse events were manageable and consistent with the proposed mechanism.

“This is the first investigational therapy to demonstrate improved OS in metastatic uveal melanoma,” said Bahija Jallal, Chief Executive Officer of Immunocore. “We believe these data demonstrate that tebentafusp has the potential to provide a meaningful difference in the treatment of metastatic uveal melanoma, a highly aggressive disease for which there is no effective standard of care.”

In a separate oral presentation on Monday April 12, Marcus O. Butler shared an analysis of previously treated uveal melanoma patients who had prolonged survival.

Two posters from the phase 2 IMCgp100-102 study are also available for on-demand viewing at the AACR website.  These analyses investigated the proposed mechanism of action (MoA), including inducing an increase in cytokines and T cell trafficking into the tumor.

Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the U.S. Food and Drug Administration (FDA) and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. Immunocore will be working with the FDA to complete submission of a BLA for tebentafusp in the third quarter of 2021.

The Company will host a conference call for industry, health and investment professionals on Tuesday, April 13th at 7:30 am ET to discuss the phase 3 IMCgp100-202 trial. The webcast can be accessed directly through this link. A replay of the webcast will be made available shortly after the conclusion of the call and archived on the Investor Relations section of the Company’s website for at least 90 days.

PLENARY AND ORAL PRESENTATIONS

Title: Phase 3 randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma

  • Date and Time: Plenary session presentation (CT002), Saturday April 10th at 11:30am – 1:30pm ET
  • Presenter: Jessica C. Hassel (PI), University Hospital Heidelberg, Heidelberg, Germany
  • Abstract #: 5342
  • Session Title: Phase III Clinical Trials

Title: Kinetics of radiographic response for tebentafusp (tebe) in previously treated metastatic uveal melanoma (mUM) patients (pts) achieving prolonged survival

  • Date and Time: Oral presentation (CT038), Monday April 12th at 1:30pm – 3:15pm ET
  • Presenter: Marcus O. Butler (PI), Princess Margaret Cancer Centre, Toronto, ON, Canada
  • Abstract #: 5338
  • Session Title: Disease-Oriented Innovative Clinical Research and Trials

POSTER PRESENTATIONS

TitleTebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells

  • Poster #517
  • Presenter: Marcus O. Butler (PI)

Title: Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp

  • Poster #1673
  • Presenter: Jessica Hassel (PI)

About Immunocore

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

About ImmTAC® Molecules

Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognise and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognise intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumours, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumours, regardless of mutational burden or immune infiltration, including immune “cold” low mutation rate tumours.

About Tebentafusp

Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. For more information about enrolling tebentafusp clinical trials for metastatic uveal melanoma, please visit ClinicalTrials.gov (NCT03070392).

About Uveal Melanoma

Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Metastatic uveal melanoma typically has a poor prognosis and has no currently accepted optimal management or treatment. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases per year in the United States). Up to 50% of people with uveal melanoma will eventually develop metastatic disease. When the cancer spreads beyond the eye, only approximately half of patients will survive for one year.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but are not limited to, statements regarding the efficacy, safety and therapeutic potential of tebentafusp, the design, progress, timing, scope and results of the Company’s clinical trials including IMCgp100-202, the anticipated timing of disclosure of results of clinical trials, plans for initiating future clinical trials and extension studies, the progress of the Company’s development programs including tebentafusp, the potential benefit of Breakthrough Therapy Designation or Orphan Drug Designation for tebentafusp, the timing of regulatory filings including estimates regarding the planned submission a BLA for tebentafusp, the likelihood of obtaining regulatory approval of any of the Company’s product candidates including tebentafusp, and the regulatory approval path for tebentafusp. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impacts of the COVID-19 pandemic on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and the uncertainties and timing of the regulatory approval process. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 25, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information except as required by law.

CONTACT:
Immunocore
Debra Nielsen, Head of Communications
T: +1 (610) 368-8602
E: debra.nielsen@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/ Sukaina Virji/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com

IIA Signs MOU with Vietnam’s Ministry of Finance

Collaboration focuses on furthering the mission of internal audit in Vietnam

Lake Mary, Florida USA, April 12, 2021 (GLOBE NEWSWIRE) — LAKE MARY, Fla., USA (April 12, 2021) — The Institute of Internal Auditors (IIA), the internal audit profession’s widely recognized advocate, educator, and provider of standards, guidance, and certifications, has signed a Memorandum of Understanding (MOU) with the Vietnam Ministry of Finance (MOF) Accounting and Auditing Supervisory Department for cooperation and collaboration in establishing and advancing the internal audit profession in Vietnam.

The IIA is the only global association for professional internal auditors. With 200,000 members in nearly 200 countries and territories, The IIA is well-positioned to support governments around the world in advancing corporate governance and risk management in their countries through effective internal audit.

In 2018, The IIA formed the IIA–Vietnam Network to support the profession by organizing a wide range of services dedicated to the education and advancement of internal auditors. On April 1, 2019, the Vietnam Ministry of Finance issued an Internal Audit Decree, which provides a legal framework for the establishment and implementation of internal audit under globally accepted standards as expressed by The IIA’s International Standards for the Professional Practice of Internal Auditing.

“We are delighted to mark this historic occasion, which represents a significant collaboration with Vietnam’s government toward defining the crucial role of internal audit in the public and private sector of this important country,” said Anthony Pugliese, President and Chief Executive Officer of The IIA. “This effort will foster transparency and effectiveness in corporate governance. Both our organizations share the common goal of establishing a strong internal audit profession, and we look forward to partnering on this imperative.”

Among key benefits, internal auditors in Vietnam will have the ability to:

  • Gain access to The IIA’s global Standards, guidance, resources, and tools
  • Participate in training programs across career levels
  • Gain access to global internal audit certifications, such as the premier Certified Internal Auditor (CIA), as well as the Internal Audit Practitioner program
  • Collaborate with local partners in developing and delivering training for internal auditors in the public and private sectors

“Together, we will continue to work toward our mutual goal to raise the profile of internal audit in Vietnam, strengthen stakeholders’ understanding of the value that internal audit brings to organizations, and advance the profession in Vietnam and globally,” Pugliese said.

Media contacts:

John Babinchak

+1-407-937-1240

John.Babinchak@TheIIA.org

Suzanne Dawson

S&C Public Relations Inc.

sdawson@scprgroup.com

+1-646-941-9140

About The Institute of Internal Auditors

The Institute of Internal Auditors (IIA) is the internal audit profession’s widely recognized advocate, educator, and provider of standards, guidance, and certifications. Established in 1941, The IIA today serves 200,000 members in nearly 200 countries and territories. The IIA’s global headquarters are in Lake Mary, Fla. For more information, visit www.theiia.org or www.globaliia.org.

Attachments

John Babinchak
The Institute of Internal Auditors
+1-407-9371240
John.Babinchak@theiia.org